These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1091 related items for PubMed ID: 23332622

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease.
    Lebovitz HE, Banerji MA.
    Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S43-50. PubMed ID: 22650224
    [Abstract] [Full Text] [Related]

  • 23. GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.
    Derosa G, Maffioli P.
    Curr Clin Pharmacol; 2012 Aug; 7(3):214-28. PubMed ID: 22432846
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.
    Briones M, Bajaj M.
    Expert Opin Pharmacother; 2006 Jun; 7(8):1055-64. PubMed ID: 16722815
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW, Torekov SS, Holst JJ.
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Combination pharmacotherapy with incretins: what works best and when?
    Over RK, Ratner RE.
    Curr Diab Rep; 2008 Oct; 8(5):361-7. PubMed ID: 18778584
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
    Consoli A, Di Biagio R.
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):5-9. PubMed ID: 22158421
    [Abstract] [Full Text] [Related]

  • 36. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L, Montanya E.
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [Abstract] [Full Text] [Related]

  • 37. Exenatide and weight loss.
    Bradley DP, Kulstad R, Schoeller DA.
    Nutrition; 2010 Mar; 26(3):243-9. PubMed ID: 20152707
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes.
    Ottney A.
    Am J Health Syst Pharm; 2013 Dec 01; 70(23):2097-103. PubMed ID: 24249759
    [Abstract] [Full Text] [Related]

  • 40. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
    Sun F, Chai S, Li L, Yu K, Yang Z, Wu S, Zhang Y, Ji L, Zhan S.
    J Diabetes Res; 2015 Dec 01; 2015():157201. PubMed ID: 25688373
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 55.